Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.
Economy · News reference
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Launches 'Meet Your Mark' Campaign to Promote Cancer Biomarker Testing
AstraZeneca has introduced a new public health campaign featuring actor Mark-Paul Gosselaar to encourage patients to discuss biomarker testing as a standard part of cancer care.
AstraZeneca Canada and Breast Cancer Canada Announce Research Funding
AstraZeneca Canada and Breast Cancer Canada are investing $200,000 in matched research funding to support initiatives addressing breast cancer survivorship.
AstraZeneca Enters Research Collaboration with Tremont AI
AstraZeneca has partnered with Tremont AI to develop and evaluate artificial intelligence models for preclinical safety assessment.
Protagonist Therapeutics Announces Participation in Four Investment Bank Conferences in November 2026
Protagonist Therapeutics announced that its senior management team will participate in four upcoming investment bank conferences throughout November 2026.
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.